Fighting resistant tuberculosis with old compounds: The carbapenem paradigm

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1755-1756

  Mainardi, J L ^a,b,c,d   Hugonnet, J E ^a,b,c   Gutmann, L ^a,b,c,d   Arthur, M ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM; CAPREOMYCIN; CARBAPENEM; CLAVULANIC ACID PLUS MEROPENEM; IMIPENEM; ISONIAZID; KANAMYCIN; QUINOLONE DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 81255143436     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03699.x     Document Type: Note

References (13)

1. World Health Organization. Global tuberculosis control 2010. WHO report 2010. Available at: (last accessed 25 October 2011).
2. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085-1094.
3. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007; 46: 11998-12004.
4. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983; 24: 429-431.
5. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Actvity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874-877.
6. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025-1026.
7. Mainardi JL, Villet R, Bugg TD, Mayer C, Arthur M. Evolution of peptidoglycan biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria. FEMS Microbiol Rev 2008; 32: 386-408.
8. Lavollay M, Arthur M, Fourgeaud M et al. The peptidoglycan of stationary phase Mycobacterium tuberculosis predominantly contains cross-links generated by L, D-transpeptidation. J Bacteriol 2008; 190: 4360-4366.
9. Mt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med 2010; 16: 466-469.
10. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-1218.
11. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol, 2002; 43: 717-731.
12. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49: 2816-2821.
13. Veziris N, Truffot C, Mainardi JL, Jarlier V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 2011; 55: 2597-2600.